Explore commentary on Cullinan Oncology, Inc Share your opinion and gain insight from other stock traders and investors. Cullinan Oncology Inc. (NASDAQ:CGEM) shares fell to a low of $28.00 before closing at $30.41. April 7, 2021. Cullinan Oncology Inc Stock Ownership Add to Watchlist. Business Description. The stock current value is $33.11. Cullinan hopes to soon file for approvals to initiate clinical studies of experimental drugs CLN-619 and CLN-049. Benzinga. Cullinan Oncology, LLC announced today the appointment of Jeffrey Trigilio as the companys Chief Financial Officer. Cullinan Oncology announced that the Food and Drug Administration has cleared Cullinan MICA's IND application for CLN-619. 04/08 01:38. Cullinan Oncology, LLC : CGEM. This letter is being provided on behalf of Cullinan Oncology, LLC, a Delaware limited liability LLC (the LLC), with respect to the LLCs Registration Statement on Form S-1 (File No. Data is currently not available. A business model adapted to the realities of drug development. Cullinan Oncology combines a unique portfolio model with innovative sourcing techniques and drug development expertise to discover and advance candidates for potentially transformative oncology drugs. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. CAMBRIDGE, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan) announced today that the Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference GlobeNewswire The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers Add to Cullinan Oncology Inc. analyst ratings, historical stock prices, earnings estimates & actuals. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. How has Cullinan Oncology's share price performed over time and what events caused price changes? Their stock opened with $21.00 in its Jan 7, 2021 IPO. Mid-Day Market Update: Why Cullinan Oncology Stock Is Skyrocketing Today. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology Cullinan Oncology General Information Description. Globe Newswire. Cullinan Oncology, Inc. Common Stock, also called Cullinan Oncology, is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. Cullinan Oncology Insiders Bought Stock Recently. The firm has no submitted 13F filings and does not appear to be an investment advisor. CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced its financial results for the first quarter ended March 31, 2021 and reported on recent business highlights. The biotech stock could have other catalysts on the way. April 07, 2021. The company additional details pertaining to Cullinan Pearls ongoing Phase 1/2a trial of CLN-081 in Non-Small Cell Lung Cancer (NSCLC) patients whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations. - Mar 30, 2021, 6:17AM. The Investor Relations website contains information about Cullinan Oncology, Inc.'s business for stockholders, potential investors, and financial analysts. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Set Alert Options Streaming Charts. CGEMs previous close was Seasonal Stock Forecasts, Stock Valuations, Predictive Stock Analytics and see the #1 stock for the next 7 days Screen For Seasonal Trends. CGEM Stock warning signs - Cullinan Oncology Inc : GuruFocus did a checkup and found warning signs for the stock. Company profile page for Cullinan Oncology LLC including stock price, company news, press releases, executives, board members, and contact information When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. To see how Cullinan Oncology, Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: CGEM stocks performance was +11.26% in the latest trading, and 0% in the past year, while Bristol-Myers Squibb Company (BMY) has traded +0.22% on the day and positioned +6.65% higher than it was a year ago. Cullinan Oncology Inc is a biopharmaceutical company. The company, previously known as Cullinan Oncology, has offered to sell 11.9 million shares of its common stock at a price of $21 each. This number entails how much is being traded in the open market. Cullinan Oncology Inc. (CGEM) Company Bio. Cullinan Oncology Reports First Quarter 2021 Financial Results GlobeNewswire. cullinan oncology inc - as of data cutoff, no grade 3 trae diarrhea at doses below 150mg bid; no grade 3 rash traes The company was founded by Patrick R. Baeuerle on 15 September, 2016 and is Overview Forecast Earnings Dividend Ownership. The CGEM shares 52-week high remains Get instant access to a free live streaming chart of the Cullinan Oncology LLC Stock. Are Insiders Buying Cullinan Oncology, Inc. (NASDAQ:CGEM) Stock? Cullinan Oncology (CGEM) stock price, charts, trades & the US's most popular discussion forums. Cullinan Oncology, Inc. to Participate +0.1201 (+0.46%) DATA AS OF Jun 29, 2021 9:36 AM ET. Cullinan Oncology, Inc key financial stats and ratios If you want to check out CGEM market capitalization, P/E Ratio, EPS, ROI, and other financial ratios, this page is your go-to hub. 04/07 10:08. Exchange: NASDAQ ->Biotechnology . The big jump came after the company announced additional data The latest closing stock price for Cullinan Oncology as of February 26, 2021 is 40.42. Cullinan Oncology has a consensus target price of $51.75, indicating a potential upside of 88.18%. 5 months ago - NASDAQ. Find the latest Cullinan Oncology, Inc. (CGEM) stock quote, history, news and other vital information to help you with your stock trading and investing. In addition to his primary financial responsibilities, Jeff will play an important role across many facets of the business, including business development, project management and investor relations. A stocks Dividend Uptrend rating is dependent on the companys price-to-earnings (P/E) ratio to evaluate whether or not a stocks dividend is likely to trend upward. Company Profile. Pipeline We are advancing a pipeline of targeted oncology and immuno-oncology therapeutic candidates and programs that are diversified by mechanism, therapeutic approach, modality, and stage of development. Cullinan Oncology Inc. (NASDAQ: CGEM) stock closed at 26.25 per share at the end of the most recent trading day (a -4.48 % change compared to the prior day closing price) with a volume of 200.33K shares and market capitalization of 1.14B.Is a component of indices and it is traded on NASDAQ exchange. Press Release reported 1 hour ago that Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearls CLN-081 in NSCLC EGFR Exon 20 Patients Event: Needham Virtual Healthcare ConferenceDate: Tuesday, April 13thTime: 11:45am EDTLocation: Virtual The The all-time high Cullinan Oncology stock closing price was 45.73 on February 19, 2021. The Company is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. Globe Newswire. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Proprietary Stock Score Ratings. In the first section, we are going to analyze the 30-day SMA of Cullinan Oncology Inc (CGEM) share price for recent 52 weeks between 2020-06-03 and 2021-06-03. At the last check today, the stocks price was $35.96, to imply an increase of 20.83% or $6.2 in intraday trading. 03/30 06:24. Information is provided 'as-is' and solely for info Get the latest news and real-time alerts from Cullinan Oncology, Inc. (CGEM) stock at Seeking Alpha. The question becomes, what are the chances the stock will continue to grow shareholders wealth in the market. Learn about the SCoRE. May 14, 2021. Find the latest Cullinan Oncology, Inc. (CGEM) stock discussion in Yahoo Finance's forum. Oncology biotech Cullinan Management increases deal size by 30% ahead of $195 million IPO. Security Date/Time Rebate Rate Fee Rate Shares Available; CULLINAN ONCOLOGY INC CGEM: 2021-06-30 22:15:03 UTC-0.4127: 0.4927: 30000: CULLINAN ONCOLOGY INC CGEM Applied BioMath will develop a systems pharmacology model CONCORD, Mass., Sept. 29, 2020 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Cullinan Oncology. Questions? Stock Price Prediction: Update at 5:00pm EST Its last market close was $29.73 an increase of 4.72% over the previous week. CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) ("Cullinan"), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced that it will provide a clinical update on CLN-081 during a webinar on Friday, June 4 th, 2021 at 10:30 am ET ("Pearl Clinical Update Webinar"). CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced its financial results for the first quarter ended March 31, 2021 and reported on recent business highlights. See the latest insider trading data and institutional ownership changes for Cullinan Oncology, Inc. (CGEM) Company Profile. Globe Newswire. If we look at who the major shareholders are, we find that insiders hold 18.39% of Cullinan Oncology, Inc. shares while 72.06% of the shares are in the hands of institutional holders. Webull provides the latest Cullinan Oncology Inc (CGEM) stock and general news. is stepping down from his day-to-day role as Chief Medical Officer, and will assume the role of Chairman The search for innovation knows no boundaries. 04/08 01:38. Get detailed information on Cullinan Oncology Inc including stock quotes, company background, company fundamentals, company financial reports and annual dividend yield in the Stock Factsheet Free forex prices, toplists, indices and lots more. Company Releases for Cullinan Oncology Inc. Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML GlobeNewswire. Trade Ideas Finds Your Next Trade in Cullinan Oncology, Inc. New Stock: Look Up. Cullinan Oncology combines a unique portfolio model with innovative sourcing techniques and drug development expertise to discover and advance candidates for potentially transformative oncology drugs. In Cullinan Oncology, Inc.Consolidated Balance Sheets (Unaudited)(in thousands, except shares and per share amounts) December 31,2020 March 31,2021 Assets Current assets: Cash and Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference. Quote Stock Analysis News Price vs Fair Value Globe Newswire. Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. Last Price $26.03 NASDAQ Previous Close - Last Trade as of 3:59PM ET 6/21/21. Cullinan Oncology, Inc. (NASDAQ:CGEM)s Major holders. PRICE ACTION $26.25. Their forecasts range from $40.00 to $55.00. On average, they anticipate Cullinan Oncology's share price to reach $48.75 in the next year. This suggests a possible upside of 40.6% from the stock's current price. Cullinan Oncology, Inc. (CGEM) stock prices were up by 18.63% shortly after market trading commenced on June 4 th, 2021, bringing the price per share up to USD$35.30 early on in the trading day. Cullinan Management, a Phase 1/2a biotech developing and investing in oncology therapies, raised the proposed deal size for its upcoming IPO on Wednesday. LAST PRICE - AT THE CLOSE. June 04, Cullinan is evaluating various doses of CLN-081 in a Phase 1/2a trial in patients with NSCLC harboring EGFRex20ins mutations that have progressed post chemotherapy. Friday, May 14, 2021. Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced that it A different approach to sourcing oncology assets. Cullinan Oncology Inc CGEM:NASDAQ. Learn more. The oncology company announced supplementary information about Cullinan Pearls ongoing Phase 1/2a trial of CLN-081 on June 4 th, 2021. Cullinan Oncology Inc. (CGEM) Company Bio. About CGEM. Cullinan Oncology reports FY results. june 4 (reuters) - cullinan oncology inc cgem.o: cullinan oncology announces phase 1/2a interim data for cullinan pearls cln-081 in nsclc egfr exon 20 patients. From GlobeNewswire News Releases. Get the hottest Get the latest Cullinan Oncology Inc (CGEM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Its lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. If a stock is valued near, or slightly below the market average, research has shown that the market expects the stocks dividend to increase. Cullinan Oncology reports FY results. $26.2801. The big jump came after the company announced additional data for its ongoing phase 1/2a study evaluating CLN-081 in treating non-small cell lung cancer (NSCLC). View detailed financial information, real-time news, videos, quotes and analysis on Cullinan Oncology, Inc. (NASDAQ:CGEM). Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. US stock market today: stock quotes, stock screener, stock charts, insiders trading, market news, portfolio tracking, and cryptocurrencies. Cullinan Oncology is an other business based in the US. CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cullinan Management, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology Cullinan Oncology Inc () Stock Market info Recommendations: Buy or sell Cullinan Oncology stock? The companys stock price has collected -3.28% of loss in the last five trading sessions. CLN-081 Trial Update. Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. Cullinan Oncology Inc. price | Cullinan Oncology Inc. Quote. Cullinan Oncology, Inc., formerly Cullinan Management, Inc. is a biopharmaceutical company. Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. CONCORD, Mass., Sept. 29, 2020 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Cullinan Oncology. Cullinan Oncology stocks (CGEM.US) are listed on the NASDAQ and all prices are listed in US Dollars. Cullinan Oncology beats Abcam on 5 of the 9 factors compared between the two stocks. SA Breaking News. Cullinan Oncology Reports First Quarter 2021 Financial Results. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. Cullinan Oncology FY20 EPS $ (3.23), Up From $ (5.48) YoY. 333-251512) (as amended, the Registration Statement), that was initially publicly filed with the Securities and Exchange Commission (the Commission) on December 18, 2020. For financial reporting, their fiscal year ends on December 31st. CGEM is DOWN -13% BELOW 20 day SMA. JUN 17 06:12:39pm CGEM. What happened Shares of Cullinan Oncology (NASDAQ: CGEM) were skyrocketing 19.5% higher as of 11:21 a.m. EDT on Friday. Below graph will show both the price and SMA of CGEM stock. Cullinan Oncology has a post-money valuation in the range of $500M to $1B as of Jun 5, 2020, according to PrivCo. Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. CLN-619 is a first-in-class monoclonal antibody designed to promote an antitumor response by engaging both natural killer and T cells through the MICA/B-NKG2D axis, with therapeutic potential for both solid and liquid tumor indications. Cullinan Oncology is funded by 17 investors. Cullinan Oncology (CEGM) Investor Presentation - Slideshow: Apr 8: Are Insiders Buying Cullinan Oncology, Inc. (NASDAQ:CGEM) Stock? Morningstar Rating. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a Foresite Capital and BVF Partners are the most recent investors. 06:30 AM ET. May 19, 2021. Shares of Cullinan Oncology (NASDAQ:CGEM) were skyrocketing 19.5% higher as of 11:21 a.m. EDT on Friday. Cullinan Oncology Reports Full Year 2020 Financial Results and Business Highlights. Scan for stocks set to soar and crash based on powerful seasonal trends plus view the stock with the most powerful seasonal trend this week Perform Advanced Searches Cullinan Oncology, Inc. (NASDAQ:CGEM) price on Friday, Jun 25, rose 5.32% above its previous days close as an upside momentum from buyers pushed the stocks value to $27.5. This information may help you make smarter investment decisions. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Cullinan Oncology, Inc.. Yahoo Finance 3/30/2021. Why Cullinan Oncology Stock Is Skyrocketing Today. Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com. The share float percentage for the stock Cullinan Oncology is based out of Cambridge. CGEM updated stock price target summary. You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here. At the end of the latest market close, Cullinan Oncology Inc. (CGEM) was valued at $29.76. CGEM is DOWN -12% since the begininning of the year. Cullinan Oncology, Inc. (NASDAQ:CGEM)s traded shares stood at 783,433 during the latest session, with the companys beta value hitting 0. Zacks Rank & Stocks to Consider. CAMBRIDGE, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan) announced today that the companys Chief Financial Officer, Jeff Trigilio, will present at the upcoming 20th Annual Needham Virtual Healthcare Conference. Cullinan Oncology, Inc.Consolidated Balance Sheets (Unaudited)(in thousands, except shares and per share amounts) December 31,2020 March 31,2021 Assets Current assets: Cash and cash equivalents $168,198 $293,537 Prepaid expenses and other current assets 2,072 6,419 Short term investments 42,008 147,337 Total current assets 212,278 447,293 Property and equipment, net 130 The company was founded by Patrick R. Cullinan Oncology, LLC, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. View Cullinan Oncology Inc. CGEM investment & stock information. Free current stock price quotes and data for Cullinan Oncology Inc (CGEM). Sector: Health Technology. Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference. Cullinan Oncology General Information Description. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Rating as of Jul 1, 2021. Business Description. Cullinan Oncology Inc. analyst estimates, including CGEM earnings per share estimates and analyst recommendations. Find real-time CGEM - Cullinan Oncology Inc stock quotes, company profile, news and forecasts from CNN Business. 2021 Stock Option and Incentive Plan and form of award agreements thereunder from Cullinan Oncology, LLC filed with the Securities and Exchange Commission. Cullinan Oncology, Inc., formerly Cullinan Management, Inc. is a biopharmaceutical company. Stock analysis for Cullinan Oncology Inc (CGEM:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Cullinan Oncology (CGEM) Stock Price History | Cullinan Oncology to Provide CLN-081 Clinical Update at ASCO 2021. Cullinan Oncology, LLC was founded in 2016 and is headquartered in Cambridge, Massachusetts. Find the latest Insider Activity data for Cullinan Oncology, Inc. Common Stock (CGEM) at Nasdaq.com. 1 Cullinan Oncology Inc (CGEM) Stock Trend Based On 30 Days Moving Average. The company was founded by Patrick R. Its lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. A number of other institutional investors have also recently [] Applied BioMath will develop a systems pharmacology model Cullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. Cullinan Oncology employs 24 staff and has a trailing 12-month revenue of around $18.9 million. Cullinan Oncology, Inc. Cullinan Oncology Completes $131.2 Million Series C Financing CAMBRIDGE, Mass., December 17, 2020 - Cullinan Oncology, LLC, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, Major holders of Cullinan Oncology, Inc. (CGEM) stock. Cullinan Oncology Inc. (NASDAQ:CGEM) went up by 17.78% from its latest closing price compared to the recent 1-year high of $59.85. CGEM | Complete Cullinan Oncology Inc. stock news by MarketWatch. Industry: Pharmaceuticals: Major. Cullinan Oncology Inc is a biopharmaceutical company. Cullinan Oncology to Provide CLN-081 Clinical Update at ASCO 2021 GlobeNewswire. Intraday shares traded counted 0.32 million, which was -15.75% lower than its 30-day average trading volume of 277.98K. Get detailed information on CULLINAN ONCOLOGY INC (CGEM.NQ) including stock quotes, financial news, historical charts, company background, company fundamentals, company financials, insider trades, annual reports and historical prices in the Company Factsheet. 03/30 06:24. 04/07 10:08. SCoRE: 53 . The biotech stock could have other catalysts on the way.
Asco Numatics Country Of Origin,
Muzik Shqip 2020 Hitet E Reja Shkarko,
Retirement Planning Articles,
How To Propagate Mugwort From Cuttings,
Elite Dangerous Powerplay Benefits,
Wanyamon Evolution Cyber Sleuth,
Which Parasite Causes Iron Deficiency Anemia,
Where Is Abercrombie And Fitch Made,